Impact of DNA damage repair defects on response to PSMA radioligand therapy in metastatic castration-resistant prostate cancer.
Privé BM, Slootbeek PHJ, Laarhuis BI, Naga SP, van der Doelen MJ, van Kalmthout LWM, de Keizer B, Ezziddin S, Kratochwil C, Morgenstern A, Bruchertseifer F, Ligtenberg MJL, Witjes JA, van Oort IM, Gotthardt M, Heskamp S, Janssen MJR, Gerritsen WR, Nagarajah J, Mehra N.
Privé BM, et al. Among authors: morgenstern a.
Prostate Cancer Prostatic Dis. 2022 Mar;25(1):71-78. doi: 10.1038/s41391-021-00424-2. Epub 2021 Jul 12.
Prostate Cancer Prostatic Dis. 2022.
PMID: 34253846